2019.Jun.27
Supplementary statement regarding the news article by the Investor and other news media
Date of occurrence of the event: Jun 27, 2019 Company name: OBI Pharma, Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A Name of mass media: Investor and other news media Content reported: Delay recruitment if global P3 Breast cancer, ADC to be submitted to FDA in […]
This article is password protected.
To view the content, please enter your password in the field below